BR112022002522A2 - Tratamento de doenças neurológicas com inibidores do complemento - Google Patents

Tratamento de doenças neurológicas com inibidores do complemento

Info

Publication number
BR112022002522A2
BR112022002522A2 BR112022002522A BR112022002522A BR112022002522A2 BR 112022002522 A2 BR112022002522 A2 BR 112022002522A2 BR 112022002522 A BR112022002522 A BR 112022002522A BR 112022002522 A BR112022002522 A BR 112022002522A BR 112022002522 A2 BR112022002522 A2 BR 112022002522A2
Authority
BR
Brazil
Prior art keywords
treatment
neurological diseases
complement inhibitors
methods
complement
Prior art date
Application number
BR112022002522A
Other languages
English (en)
Inventor
J Read Simon
Ricardo Alonso
Sayegh Camil
Xu Xiangyang
Tang Yalan
Tang Guo-Qing
Original Assignee
Ra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ra Pharmaceuticals Inc filed Critical Ra Pharmaceuticals Inc
Publication of BR112022002522A2 publication Critical patent/BR112022002522A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

TRATAMENTO DE DOENÇAS NEUROLÓGICAS COM INIBIDORES DO COMPLEMENTO. A presente invenção refere-se a métodos para tratar indicações inflamatórias com compostos e composições inibidores do complemento. Estão incluídos compostos e métodos para o tratamento da esclerose lateral amiotrófica (ALS).
BR112022002522A 2019-09-12 2020-09-11 Tratamento de doenças neurológicas com inibidores do complemento BR112022002522A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962899488P 2019-09-12 2019-09-12
US202062969742P 2020-02-04 2020-02-04
US202062988587P 2020-03-12 2020-03-12
US202063021742P 2020-05-08 2020-05-08
PCT/US2020/050422 WO2021050885A1 (en) 2019-09-12 2020-09-11 Neurological disease treatment with complement inhibitors

Publications (1)

Publication Number Publication Date
BR112022002522A2 true BR112022002522A2 (pt) 2022-08-16

Family

ID=72659901

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022002522A BR112022002522A2 (pt) 2019-09-12 2020-09-11 Tratamento de doenças neurológicas com inibidores do complemento

Country Status (8)

Country Link
US (1) US20220370548A1 (pt)
EP (1) EP4028126A1 (pt)
JP (1) JP2022547581A (pt)
CN (1) CN114423445A (pt)
BR (1) BR112022002522A2 (pt)
CA (1) CA3150594A1 (pt)
MX (1) MX2022003013A (pt)
WO (1) WO2021050885A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240100069A1 (en) * 2022-09-07 2024-03-28 Amylyx Pharmaceuticals, Inc. Methods and Compositions for Treating Amyotrophic Lateral Sclerosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110172126A1 (en) 2008-09-03 2011-07-14 Xenome Ltd Libraries of peptide conjugates and methods for making them
BR122023024819A2 (pt) 2014-06-12 2023-12-26 Ra Pharmaceuticals, Inc. Uso de um polipeptídeo para inibir a clivagem de c5 em um sistema celular
US9937222B2 (en) 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
CN108697759B (zh) 2015-12-16 2022-08-02 Ra制药公司 补体活性的调节剂
EP3551210A1 (en) 2016-12-07 2019-10-16 RA Pharmaceuticals, Inc. Modulators of complement activity
WO2020086506A1 (en) 2018-10-22 2020-04-30 Ra Pharmaceuticals, Inc. Neurological disease treatment with zilucoplan
JP2022524078A (ja) * 2019-03-08 2022-04-27 ラ ファーマシューティカルズ インコーポレイテッド 深部組織浸透性ｃ５阻害剤としてのジルコプラン

Also Published As

Publication number Publication date
CA3150594A1 (en) 2021-03-18
WO2021050885A1 (en) 2021-03-18
JP2022547581A (ja) 2022-11-14
EP4028126A1 (en) 2022-07-20
US20220370548A1 (en) 2022-11-24
CN114423445A (zh) 2022-04-29
MX2022003013A (es) 2022-04-07

Similar Documents

Publication Publication Date Title
JOP20220245A1 (ar) أجسام مضادة ترتبط تحديداً بـ masp-3 لعلاج أمراض واضطرابات متنوعة
CL2019002535A1 (es) Composiciones para modular la expresión de sod-1.(divisional solicitud 201801897).
MX2023005804A (es) Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7).
CO2019006622A2 (es) Derivados de pirazol como inhibidores de malt1
MX2020011528A (es) Inhibidores heterociclicos sustituidos de ptpn11.
BR112018000691A2 (pt) inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias
EA201992674A1 (ru) Тиенопиридины и бензотиофены в качестве ингибиторов irak4
BR112021016620A2 (pt) Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais
BR112017020999A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
BR112021026668A2 (pt) Compostos heterocíclicos como inibidores de bet
MA39219B1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
MX2024004318A (es) Inhibidores de proteina tirosina fosfatasa y sus metodos de uso.
EA201792496A1 (ru) Способы лечения воспаления или нейропатической боли
MX2020003961A (es) Uso de inhibidores de p38 para reducir la expresion de dux4.
BR112018069147A2 (pt) composto da fórmula iii, composição farmacêutica, método de inibição da função de fimh e método de tratamento de uma doença mediada por fimh
BR112022010082A2 (pt) Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica
IN2015DN00370A (pt)
EA201890647A1 (ru) Лечение нейродегенеративных заболеваний
BR112017025263A2 (pt) método para o tratamento de doença neurológica
EA201792641A1 (ru) Ингибитор оси igfbp3/tmem219 и диабет
BR112022017099A2 (pt) Composto, composição farmacêutica, método para inibição de ripk1, método para tratamento de uma doença mediada por ripk1 e método para tratamento de lesão no snc
BR112022005895A2 (pt) Inibidores de aldose redutase para tratamento de deficiência de fosfomanomutase 2
BR112022002522A2 (pt) Tratamento de doenças neurológicas com inibidores do complemento
BR112022003584A2 (pt) Compostos de pirrolopirimidina inibidores de perk

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DAS PRIORIDADES US 62/899,488, US 62/969,742, US 62/988,587 E US 63/021,742 POR AUSENCIA DE CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI NO 2679, DE 10/05/2022

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2747 DE 29-08-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.